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Abstract 
 
EXERCISE PERFORMANCE AND PERCEPTION OF BREATHLESSNESS AFTER 
CAFFEINE INGESTION IN CYCLISTS 
 
Erica Larson 
B.S., James Madison University  
M.S., Appalachian State University 
 
 
Chairperson:  R. Andrew Shanely, Ph.D. 
 
 
Introduction: Caffeine (CAF) is commonly ingested as an ergogenic aid among 
cyclists, in part, due to its effect on pain perception. CAF also may improve exercise 
performance by altering the perceptions related to ventilatory work and dyspnea. 
Purpose: The purpose of this study was to evaluate exercise performance, breathlessness, 
and leg pain perception in trained cyclists during a fixed work time trial after the 
ingestion of a moderate dose of caffeine. Methods: Nine male cyclists completed 
pulmonary function testing and a peak aerobic capacity test (V̇O2peak: 60.8±5.7 ml·kg-
1·min-1). During visit two, cyclists completed a fixed-work familiarization time trial (TT) 
equivalent to a distance of 20-km. Subsequently, and on separate days, subjects 
completed in a randomized, counterbalanced order, TTs with ingestion of a placebo 
(TTPLA) or caffeine (TTCAF; 5 mg·kg-1). Elapsed time, ventilatory dynamics, and 
perceptual responses were measured every 10% of the distance during each TT. Data is 
expressed mean ± SEM. Results: Elapsed time was significantly reduced during TTCAF 
v 
 
compared with TTPLA (33.5±2.8 vs. 35.5±2.7 min, p < 0.01). RPB did not differ between 
TTCAF and TTPLA at any interval (p = 0.755). A main effect was observed in ventilation 
during TTCAF when compared with TTPLA (p = 0.019). A main effect was observed in 
integrated inspiratory mouth pressure during TTCAF when compared with TTPLA (p = 
0.040). Discussion: These results demonstrate that consuming a moderate dose of 
caffeine enhances exercise performance and increases ventilatory work without altering 
RPB.  
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Chapter 1 
Introduction 
Background 
Caffeine is a ubiquitous and legal drug that is highly popular among athletes for 
its known exercise performance-enhancing capabilities, as well as its negligible health-
related side effects (Warren et al. 2011; Ali et al. 2016; Duncan et al., 2013; Black et al., 
2015; Talanian and Spriet, 2016; Woolf et al., 2008; Astorino et al., 2012a; Paton et al. 
2015; Killen et al. 2013; Tarnopolsky, 2008b). Caffeine is readily available in food and 
drink, rendering athletes capable of ingesting it as part of their habitual diet. In addition 
to habitual consumption, athletes may purposely ingest caffeine as an ergogenic aid to 
improve athletic or exercise performance. This is a typical practice among endurance 
athletes, as it may give them an extra “push” during competition (Del Coso et al., 2011; 
Graham 2001, McLellan et al. 2016; Higgins et al., 2016; Outram and Stewart, 2015). 
Caffeine can be found in coffee, energy gels such as Cliff Shot, Hammer Gel and Honey 
Stinger, and sports drinks and bars.  
There have been studies to date in which the effects of caffeine have examined 
cycling performance (Glaister et al., 2015a; Talanian and Spriet, 2016; Astorino et al., 
2012b; Ivy et al., 2009b; Smolka and Kumstat, 2014; Jenkins et al., 2008). Factors such 
as dosage, training status, time of ingestion and history of caffeine usage can affect the 
performance enhancing abilities of caffeine (Graham 2001; Davis and Green, 2009; 
Doherty and Smith, 2005; Higgins et al., 2016). This variability has led to research 
examining differences in performance with varying doses, distances and training status.  
Previous research has shown performance enhancing effects with dosage amounts 
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between 3-6 mg/kg body weight but no established minimal or maximal guidelines have 
been established to produce optimal enhancements in performance (Graham, 2001; 
McLellan et al., 2016; Higgins et al., 2016). A moderate dose of caffeine is 
approximately equivalent to 5 mg·kg-1 body weight, which equates to two-three cups of 
coffee. One cup of coffee has approximately 80-100 mg of caffeine. 
An area of research to focus on, in relation to caffeine, is its effect on perceived 
pain during exercise. There also exist studies that have examined caffeine ingestion on 
pain perception and rating of perceived exertion (RPE) during exercise (Motl et al., 2006; 
Backhouse et al, 2011; Killen et al., 2013; Astorino et al., 2012b; Green et al., 2017; 
Gliottoni et al., 2009). Caffeine increases time to fatigue through its effect on the central 
nervous system (Kalmar and Cafarelli, 2004) and is considered an adenosine antagonist. 
When it binds to the adenosine receptors it promotes the release of various 
neurotransmitters such as dopamine, serotonin, and epinephrine, thus leading to a 
modified pain perception (Davis and Green, 2009).  Exercising vigorously for extended 
periods of time can elicit feelings of pain in some individuals. In 1979, the International 
Association for the Study of Pain defined pain as an “unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or describe in terms of such 
damage” (Merskey, 2002). Specifically, in cycling, pain can be felt in the quadriceps 
muscle group, along with other skeletal muscles within the lower extremities and lower 
back muscles.  
Ventilation increases as a function of exercise intensity. This is due to a higher 
demand of oxygen by working muscles resulting in more carbon dioxide (CO2) to be 
expelled from the body. Up until a certain exercise intensity, an individual may not 
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recognize increases in ventilation needed to meet demands of the working body 
(Campbell and Howell, 1963). This increase in ventilation can result in an increase in 
perception of breathlessness while exercising. Breathlessness is defined as, “an 
unpleasant sensation of labored breathing” (Burki, 1987a; Burki and Lee 2010b). Cycling 
can elicit a feeling of breathlessness while exercising vigorously. Caffeine has been 
shown to reduce fatigue and effort associated with the respiratory muscles by blocking 
central adenosine receptors (Kawai et al., 1995), which is the same mechanism in 
decreasing pain perception.  
There appears to be a lack of research when examining rate of perceived 
breathlessness during exercise and after caffeine ingestion in healthy individuals. There 
have been no studies to date in which these variables have been assessed during a fixed 
work time trial equivalent to 20-km.  
 
Statement of the Problem 
The purpose of this study is to evaluate the rate of perceived breathlessness after 
the ingestion of a moderate dose of caffeine in trained male cyclists, while also 
examining differences in pain perception and performance.  
 
Hypotheses 
The following hypotheses were tested:  
Hypothesis 1: Time to complete a 20-km time trial will be decreased following 
caffeine ingestion compared with that following placebo ingestion.  
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Hypothesis 2: Ratings of perceived breathlessness (RPB) during a 20-km time 
trial will be similar following caffeine ingestion compared with that following placebo 
ingestion. 
Hypothesis 3: Ratings of perceived unpleasantness (RPU) during a 20-km time 
trial will stay the same following caffeine ingestion compared with that following 
placebo ingestion. 
 Hypothesis 4: Ratings of perceived exertion (RPE) during a 20-km time trial will 
be decreased following caffeine ingestion compared with that following placebo 
ingestion.   
Hypothesis 5: Ratings of leg muscle pain during a 20-km time trial will be 
decreased following caffeine ingestion compared with that following placebo ingestion.   
Significance of the Study 
This study will contribute to the postulated mechanisms underlying the ergogenic 
effect of caffeine. Discovering another potential avenue, other than decreased pain 
perception and increases in fat oxidation, as to how caffeine can enhance performance, is 
important to athletes who consume caffeine. This study will be specifically beneficial to 
athletes who compete in a 20-km distance. It will also be beneficial because the dosage of 
caffeine to be studied (5mg·kg-1) is applicable as it is approximately the amount many 
cyclists, who are caffeine consumers, would drink before a competition or race.  
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Summary  
Caffeine is an extremely popular ergogenic aid that enhances exercise 
performance. When athletes reach an elite level, additional gains in performance within 
their field are difficult to achieve. Consuming caffeine doses within WADA levels may 
give some athletes the additional “push” they need to improve performance. 
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Chapter 2 
Review of Literature 
Introduction 
 
It has been well established that caffeine has the ability to enhance physical work 
capacity, causing many athletes to consume it before competition (Warren et al., 2011; 
Ali et al., 2016; Duncan et al., 2013; Black et al., 2015; Talanian and Spriet, 2016; Woolf 
et al., 2008; Astorino et al., 2012b; Paton et al., 2015; Killen et al., 2013). Moderate to 
high intensity exercise is associated with naturally occurring pain in the muscles that are 
activated. The sensation of pain can be described as burning, tiring, cramping, 
exhausting, intense and sharp (Cook et al., 1997). Caffeine has the ability to attenuate 
pain during exercise (Gliottoni et al., 2009; Motl et al., 2006) by acting on peripheral and 
central adenosine receptors throughout the body.  
What is Caffeine?  
The International Olympic Committee (IOC) originally banned caffeine during 
competition in 1962 but removed it from the list in 1972 (Weinberg and Bealer, 2001). 
The uncertainty of caffeine’s effects led the IOC to go back and forth on their decision to 
ban athletes from consuming it. Due to reported bouts of caffeine abuse in sports 
competition, the World Anti-Doping Agency (WADA) relisted caffeine as a doping agent 
from 1984-2004 ( Del Coso et al., 2011). To differentiate between social and 
performance enhancing amounts, the IOC limited the amount of consumption during 
competition to 12 μg/ml from 1984-2004.  Due to the individual differences in caffeine 
clearance, caffeine is considered part of a “monitoring program” by the WADA, with no 
upper limit established for a positive test outcome.  
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The lifted ban on caffeine has led to analysis of in-competition urine caffeine 
levels in athletes of varying sports.  Del Coso et al., (2011) measured urine levels of 
athletes and determined that participants from endurance sports have higher levels of 
caffeine than power athletes, such as gymnastics tennis or wrestling. Examining the 
effects of caffeine in endurance athletes, like cyclists, is important to determine and 
solidify its ergogenic effects. 
Caffeine is ubiquitous in nature, with traces of it seen in many foods and drinks. 
The main dietary sources of caffeine are found in coffee, tea, mate, guarana and soft 
drinks (Graham, 2001). Caffeine levels vary across coffee types and are dependent on the 
type of bean used, brewing method and roasting time. Caffeine is a trimethylxanthine and 
catabolized by the liver via the cytochrome P450 system to dimenthylxanathines. The 
liver demethylates caffeine into three dimenthylxanthines; paraxanthine, theophylline and 
theobromine, which are then further catabolized. Paraxanthine is responsible for 
increasing lipolysis, which helps to release glycerol and fatty acids into the blood to be 
used as fuel (Davis and Green, 2009; Graham, 2001). Theobromine, most commonly 
found in cocoa, is a vasodilator and to some degree a stimulant of smooth muscle 
(Graham and Spriet, 1995). It was formerly used as a diuretic for the treatment of angina 
and hypertension. Theophylline is a bronchodilator and induces relaxation of smooth 
muscle within the bronchial tree (Graham and Spriet, 1995). It was formerly used to treat 
patients with chronic obstructive pulmonary disorder (COPD) and is currently used to 
treat asthma (Graham and Spriet, 1995). Paraxanthine and theophylline do not increase in 
the circulation to a concentration that is considered active indicating they do not have as 
great of an effect as theobromine (Graham and Spriet, 1995).  
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Mode of Action 
Caffeine is similar in structure to adenosine, allowing it to bind to adenosine 
receptors. This mechanism blocks adenosine from attaching to the adenosine receptor. 
Adenosine aids in cellular energy transfer and plays a role in signaling various pathways 
(Ribeiro and Sebastiao, 2010). When adenosine attaches to adenosine receptors in the 
brain, it acts as a central nervous system depressant. This promotes sleep and vasodilation 
allowing for more blood flow to the brain (Ribeiro and Sebastiao, 2010).   
There are four G-protein coupled adenosine receptors, A1, A2a, A2b and A3. Each 
receptor has a unique distribution throughout the body (McLellan et al., 2016). 
Adenosine receptor density varies among individuals and can increase with high amounts 
of caffeine intake (McLellan et al., 2016).  Adenosine receptors are found in many tissues 
throughout the body including the brain, heart, smooth muscle, adipocytes and skeletal 
muscle (Graham, 2001, Higgins et al., 2016). There is difficulty in determining which 
tissues caffeine directly affects due to receptors being distributed throughout the body. 
This also makes it challenging to determine which tissues are critical in the ergogenic aid 
function of caffeine.  
Caffeine will specifically work to block A1 and A2a adenosine receptors, a 
mechanism behind caffeine attenuating pain during exercise (Ribeiro and Sebastiao, 
2010). A1 and A2a receptors are expressed in the brain and periphery (Ribeiro, 2010). 
Adenosine receptors appear to inhibit the release of neurotransmitters, such as serotonin, 
dopamine, and acetylcholine, in the central nervous system. Caffeine is considered an 
adenosine antagonist, thus, when it binds to the adenosine receptors it promotes the 
release of these various neurotransmitters mentioned above. Caffeine also has the ability 
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to cross the blood brain barrier, and effect a variety of brain centers which may lead to 
the feelings of increased alertness and vigilance (McLellan et al., 2016). 
Optimal Doses and Timing 
Caffeine’s popularity and abundant nature creates difficulty in ensuring it is not in 
athlete’s circulation during competition. As previously mentioned, the IOC has 
established a legal limit of 12 μg of caffeine per ml of urine. This limit is high, as it 
allows for an acute consumption of 9 mg·kg-1 body weight (BW) of caffeine. The 
consumption of 9 mg·kg-1 BW is generous and forgiving to athletes who are habitual 
consumers. Previous research has shown performance enhancing effects with dosage 
amounts between 3-6 mg·kg-1 BW (Graham, 2001; McLellan et al., 2016; Higgins et al., 
2016). No established minimal or maximal value of caffeine consumption has been found 
to produce optimal performance enhancement. Sufficient absorption time and attainment 
of peak circulating concentrations within the body is 60 minutes post-consumption 
(Graham, 2001). Conflicting research shows that caffeine may reach peak plasma 
concentration anywhere from 1-3 hours post-consumption (Skinner et al., 2013).  
There is much variation between individuals reaching peak plasma concentration 
levels. Most research offers no information on plasma concentration of caffeine making it 
difficult to analyze (Astorino 2012; Smolka and Kumstat 2014; Jacobson et al., 1992; 
Wallman et al., 2010; Paton et al., 2015). More research is needed in this area to 
determine if there are other factors, such as training status or caffeine consumption, 
which may affect when peak levels are achieved.  
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Consuming Caffeine at Rest 
While consuming caffeine at rest, there is an increase in ventilation, heart rate, 
blood pressure and systemic vascular resistance (Brown et al., 1993). The mechanism 
behind caffeine increasing ventilation is not completely understood (Kraaijenga et al., 
2015). After the ingestion of caffeine, tidal volume and alveolar ventilation will increase 
(Williams and Parsons, 2011). Tidal volume is the amount of air breathed in and out 
during inhalation and exhalation (Cloutier, 2007). Alveolar ventilation is the rate of air 
flow that the gas exchange areas of the lung encounter during inhalation and exhalation 
(Cloutier, 2007).  When tidal volume and alveolar ventilation increase, ventilation will 
become more efficient during exercise (Birnbaum, 2004). This mechanism may be due to 
adenosine receptor antagonism in the respiratory center. Caffeine can also improve the 
contractility of the diaphragm, the primary inspiratory respiratory muscle, leading to an 
increase in ventilation (Kraaijenga et al., 2015). The metabolizing agents of caffeine can 
also improve ventilation through a bronchodilating effect.  
Caffeine will stimulate the central nervous system and will improve CO2 
sensitivity (Kraaijenga et al., 2015). Caffeine can increase levels of angiotensin II, a 
vasoconstrictor causing an increase in blood pressure. Angiotensin II also promotes the 
release of catecholamine’s that increase heart rate (Van Soeren et al., 1993). Blood 
pressure is increased by an increase in angiotensin II and epinephrine (Brown et al., 
1993). The increase seen in heart rate will be related to the increase seen in blood 
pressure.  
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Habitual vs. Nonusers Response to Caffeine 
There is much variability when examining responses between habitual and 
nonusers after the ingestion of caffeine. Gliottoni et al., (2009) examined college-aged 
males’ quadriceps muscle pain in low and high caffeine consumers during a 30 minute 
cycling bout. Low caffeine consumers (<100 mg·day-1, n=12) and high caffeine 
consumers (>400 mg·day-1, n=13) ingested 5mg/kg of caffeine or a placebo pill and then 
completed the cycling bout. The results indicate that there was no significant difference 
in muscle pain in the low or high caffeine users (Gliottoni et al., 2009).  Tarnopolsky et 
al., (1989a) examined metabolic and physiological differences in habitual caffeine users 
(200 mg/d) after a 90-minute running bout. There was no difference in VO2, heart rate, 
RER, or RPE, however, plasma free fatty acid levels increased after caffeine 
consumption. McClaran and Wetter (2007) examined the effect of low doses of caffeine 
in non-habitual users during a steady state cycling bout. There was no difference in 
performance between the placebo and caffeine trials. After chronic consumption of 
caffeine, theophylline and paraxanthine have shown to decrease clearance at rest (Van 
Soeren,1993). The differences in plasma concentrations of dimenthylxanathines in 
habitual and nonusers of caffeine may contribute to the varying results seen. 
Trained vs. Untrained Responses to Caffeine 
There are varying results when comparing trained and untrained individuals and 
responses in performance after ingestion of caffeine. Caffeine may have a greater 
influence on trained individuals rather than untrained individuals due to a greater degree 
of muscle and tissues (Collomp et al., 1992; Graham, 2001). This increase in muscle and 
tissues would potentially allow caffeine to act on more tissues, thus producing a greater 
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effect.  In studies examining trained subjects, significantly lower respiratory exchange 
ratio (RER) values, after the ingestion of caffeine, have been reported (Bell et al., 2002; 
Costill et al., 1978; Graham and Spriet, 1995). This is indicative of a greater reliance on 
fatty acids as a fuel source compared to untrained individuals which may rely more on 
carbohydrates as fuel. This can be beneficial in cycling as the larger skeletal muscles 
used in the legs are more responsive to fat mobilization (Weinberg and Bealer, 2001).  
 Wallman et al., (2010) examined the effect of caffeine (6 mg·kg-1 BW) on ten 
sedentary females who were non-caffeine users, during a cycling bout. The results 
indicate there was no significant improvement in performance between the trials. 
Untrained individuals may have less muscle and tissues to respond to caffeine so it may 
be beneficial for them to ingest a higher dose.  
A study done by Collomp et al., (1992) examined performance after acute 
caffeine ingestion (250mg) in trained and untrained swimmers during two 100m sprints. 
Caffeine only increased performance in the trained subjects.  Lactate increased in both 
trained and untrained subjects (Collomp et al., 1992). This difference in performance may 
be attributed to the ergogenic effects of caffeine and an enhancement of buffering 
capacity in the trained individuals compared to the untrained. 
Collomp et al., (1992) and Astorino et al., (2012b) examined performance after 
caffeine ingestion in trained and untrained subjects. The results from both studies found 
significant improvement of performance in the trained subjects (Collomp et al., 1992; 
Astorino et al., 2012b).  Smolka and Kumstat (2014) examined differences in mean 
power output in sub-elite and elite cyclists and found that the caffeine significantly 
increased mean power output in the sub-elite cyclists but not in the elite cyclists. These 
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results indicate that regardless of the dosage, caffeine is not an ergogenic aid in 
professional level cyclists. There is evidence to support, regardless of fitness level, 
caffeine aids in individuals being able to perform more work, and work for a longer 
period of time (Ali et al., 2016; Duncan et al., 2013; Ivy et al., 2009b; Talanian and 
Spriet, 2016). Further research is warranted to better understand the physiological effects 
of caffeine on individuals with varying fitness levels.   
Physiological Mechanisms of Improving Performance  
The mechanisms behind caffeine enhancing performance include adenosine 
receptor antagonism, direct effects on skeletal muscle and enhanced substrate availability 
(Graham, 2001). There are a multitude of mechanisms behind caffeine’s performance 
enhancing abilities, which is seen in Figure 2. The decrease in perception of fatigue, 
during prolonged exercise, is influenced by caffeine affecting the central nervous system 
(Powers and Howely, 2012).  As mentioned previously, caffeine acts as an adenosine 
receptor antagonist, resulting in decreases in pain perception, and increases arousal and 
locomotor activity (Davis and Green, 2009). Caffeine aids in delaying fatigue by acting 
as an adenosine antagonist (Preedy, 2012).  
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Muscle  
 
 
↑ Ca2+ Handling       blood [lactate]  
 
 
 
                                                 
 
Figure 1. Proposed mechanisms for ergogenic aid of caffeine (Adaptaed from Preedy, 2012). 
 
Caffeine may improve performance through enhanced tension development in 
fatigued skeletal muscle (Davis and Green, 2009). The enhancement in fatigued muscles 
is reported to be due to increased calcium release from ryanodine receptors. Ryanodine 
receptors help facilitate the release of calcium from the sarcoplasmic reticulum (Powers 
and Howley, 2012).  
Caffeine also enhances performance through mobilization of glucose and fat 
(Powers and Howley, 2012). This aspect has received much attention because it is the 
primary means by which caffeine exerts an ergogenic aid effect (Powers and Howley, 
2012). Caffeine increases levels of glucose and free fatty acid utilization through 
stimulation of adrenaline secretion (Graham, 2001; Higgins et al., 2016). Caffeine 
inhibits phosphodiesterase enzymes, which allow for an increase in intracellular cyclic 
adenosine monophosphate (cAMP) (Davis and Green, 2009). An increase in cAMP, 
would lead to greater lipolysis and fat metabolism and ultimately glycogen sparing 
(Davis and Green, 2009). Inhibiting phosphodiesterase will increase the power of release 
 Altered [K+] Brain  ↑ Motor unit 
recruitment 
Adenosine 
antagonism 
↑ Reaction time, alertness, 
and mood 
Anti-fatigue effects 
 ↑ Performance 
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of catecholamine’s, which increase heart rate and blood pressure (Tavares and Sakata, 
2012).  
Outcomes 
 Three main outcomes to be examined: differences in rate of perceived 
breathlessness, pain perception, and performance.  
Breathlessness 
Feelings of breathlessness can occur when there are increases in respiratory drive 
or the respiratory system is exposed to mechanical load (Manning and Schwartzstein, 
1995). Breathlessness is multifaceted and involves three different sensations; air hunger, 
work/effort and chest tightness (Nishino, 2011). Air hunger arises when there is a 
mismatch between pulmonary ventilation and the drive to breathe (Lansing, 2009). Work 
of breathing can be perceived as uncomfortable when breathing frequency or tidal 
volume increases above normal levels, weak respiratory muscles, and less than optimal 
length of the respiratory muscles (Lanstang. 2009). Chest tightness is mainly related to 
bronchoconstriction and is related to localized tightness within the chest or lungs 
(Lanstang, 2009). All of these sensations can lead to feelings of breathlessness while 
exercising. It has been proposed that breathlessness occurs when there is a mismatch 
between afferent information from the receptors of the respiratory system and the central 
nervous system (Manning and Schwartzstein, 1995).  
Caffeine ingestion increases ventilation at rest and during exercise (Chapman and 
Mickleborough, 2009a).  During exercise, ventilation and alveolar ventilation increase 
(Sheel and Romer, 2004). At lower intensities, increases in breathing frequency and tidal 
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volume ultimately lead to pulmonary ventilation increasing. However, at higher exercise 
intensities, tidal volume will plateau (around 50-60% vital capacity) and ventilation rises 
by additional increases in breathing frequency (Sheel and Romer, 2004). 
 Birnbaum (2004) examined the effects of 7 mg·kg-1 BW of caffeine in 10 
distance runners (n=5 M, n=5 F) during a 30-minute run at 70% of the subjects VO2 max. 
Researchers found pulmonary ventilation increased during the caffeine trial, along with 
tidal volume and alveolar ventilation (Birnbaum, 2004).  Subjects decreased breathing 
frequency but increased tidal volume, during the caffeine trial, which increased 
ventilation.  This is indicative of the respiratory muscles becoming more efficient, which 
was related to the subjects’ decrease in RPE (Birnbaum, 2004). The increase in efficiency 
may be due to the bronchodilating effect in which caffeine exerts.  
Increases in pulmonary ventilation during exercise with ingestion of caffeine have 
been seen in multiple studies (D’Urzo et al., 1990; Powers et al., 1986; Chapman and 
Stager, 2008b). Results from other studies examining caffeine on pulmonary ventilation 
have shown no change in pulmonary ventilation (Tarnopolsky et al., 1989a; Sasaki et al., 
1987). If there is an increase in pulmonary ventilation during exercise, this could result in 
increased alveolar oxygen partial pressure, which could ultimately improve arterial 
hemoglobin saturation and delivery of oxygen to the working skeletal muscle (Chapman 
and Mickleborough, 2009a).  None of these studies examined specifically caffeine’s 
influence on the subjects’ perception of breathlessness. 
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Pain Response 
Exercise can induce feelings of pain that are acute and transient, meaning these 
feelings will dissipate after exercise has ceased. In 1979, the International Association for 
the Study of Pain defined pain as an “unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or describe in terms of such damage” 
(Merskey, 2002.) This emphasizes that pain is multi-dimensional and complex in nature. 
The process by which information about tissue damage is sent to the central nervous 
system is through nociception. Nociceptors are sensory receptors that are sensitive to 
tissue damage. Nerve pulses are transmitted to the spinal cord and brain, via the axons of 
the primary afferent neurons to the dorsal horn of the spinal cord. Ingesting caffeine may 
attenuate this pain response while exercising, which can decrease RPE and increase the 
work that is achievable (Ribeiro and Sebastiao, 2010).  
Keogh and Witt (2001) examined the pain response in males and females after 
caffeine ingestion while placing their hand in ice water. There were no significant 
differences in pain tolerance or threshold between the males and females in the placebo 
trial. Significant differences did exist in pain tolerance and threshold during the caffeine 
trial. This was thought to be due to an increase in stress felt by the subjects after caffeine 
consumption, resulting in a higher pain tolerance and threshold.  However, the women 
exhibited a lower pain tolerance then the men during the caffeine trial (Keogh and Witt, 
2001).  
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Performance  
Caffeine is widely known as an ergogenic aid that can enhance mood, increase 
vigilance, delay feelings of fatigue, increase time to exhaustion, and decrease sensations 
of pain. Increases in aerobic performance after caffeine ingestion have been measured 
(Ivy et al., 2009b; Motl et al., 2006; Paton et al., 2015; Backhouse et al., 2011; Talanian 
and Spriet, 2016). Ivy et al., (2009) found a 4.7% increase in performance during a 1-
hour cycling time trial after ingestion of 500 ml of Red Bull (160 mg of caffeine) when 
compared to the placebo. During the time trial, RPE was not statistically different at any 
time during the placebo and energy drink trial, indicating the subjects were able to 
exercise more intensely during the caffeine trial but with the same perception of effort. 
There was no difference in substrate utilization between the trials, however as exercise 
duration increased, fat oxidation increased and carbohydrate oxidation decreased.  
Skinner et al., (2013) examined the effects of 6 mg·kg-1 BW of caffeine on 14 
highly trained male cyclists during a 40km time trial and also found no statistically 
significant differences in RPE during the placebo and experimental trial with caffeine. 
However, performance improved significantly with the caffeine (Skinner et al., 2013).  
Talanian and Spriet, (2016) had highly trained male and female cyclists ingest 
two different doses of caffeine (1.5 mg·kg-1 BW and 2.9 mg·kg-1 BW) during a 120-
minute bout of exercise. Improvements in performance were measured with both doses. 
Unlike most other studies, blood samples were taken to measure caffeine concentrations. 
Caffeine concentrations were significantly higher during both doses of caffeine compared 
to the placebo. 
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 Foad et al., (2008) examined the pharmacological and psychological effects of 5 
mg·kg-1 of caffeine in highly trained male cyclists during a 40km time trial. All of the 
subjects completed 14 trials. In some of the trials, the subjects were informed they 
received caffeine, informed they received caffeine but was given a placebo, and they 
were informed they were given a placebo.  The results indicate that performance was 
enhanced whether subjects believe they had ingested it or not (Foad et al., 2008).  
Summary 
The purpose of this study was to evaluate exercise performance, breathlessness, 
and leg pain perception in training cyclists during a fixed work time trial after the 
ingestion of a moderate dose of caffeine. 
It was hypothesized that following caffeine consumption, subjects would perform 
the time trial faster, RPB and RPU would be similar and RPE and leg muscle pain would 
decrease.  
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Chapter 3 
Methods 
 
Participants 
Following approval of the study from Appalachian State University Institutional 
Review Board (IRB# 17-0302), highly trained male cyclists 18 to 50 years old were 
recruited to participate in this study. Subjects were initially screened by telephone to 
ensure they had no prior health or medical conditions that would prevent them from 
completing the study. Individuals who regularly consumed a large amount of caffeine 
(e.g., >4 cups of coffee per day) were excluded from participation as well as individuals 
who consumed little to no caffeine daily (e.g., <1 cup of coffee daily). Subjects were 
excluded under conditions of respiratory, cardiovascular, metabolic, or renal disease, or a 
history of cigarette smoking greater than or equal to one-half of a pack-year.  The 
subjects were also required to be bicycle training approximately three hours a week for 
the past six months. A minimum V̇O2peak of 53 mL·kg-1·min-1 was met by each subject. 
Prior to each visit, subjects were asked to refrain from strenuous exercise (24 hours), 
caffeine (12 hours) and arrive in a fully rested and hydrated state.  
 
Experimental Design  
A double-blind, randomly-assigned, placebo-controlled experimental design was 
employed to examine the effect of caffeine on perceptual responses and exercise 
performance. All subjects visited the laboratory on four occasions. Subjects completed 
the informed consent process, a medical health history questionnaire, pulmonary function 
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testing, and peak exercise test during the initial visit. Height and weight also were 
measured during the visit.  
 Visit two consisted of a fixed-work familiarization TT. Visits three and four 
consisted of subjects completing a fixed-work TT under placebo (TTPLA) and caffeine 
(TTCAF) conditions in a randomly-assigned, double-blind manner. All exercise visits were 
separated by a minimum of 48 hours. The total time to complete the study required by 
subjects was approximately 7-9 hours.  
 
Pulmonary Function  
All subjects completed spirometry and lung volume tests in a body plethysmograph 
(Carefusion Vmax 62J Auto Box, Yorba Linda, CA) according to ATS/ERS guidelines 
(European and Society 2002). Subjects performed the spirometry procedures in a seated 
position while breathing room air, with nasal breathing occluded by a nose clip. The 
procedure for all spirometry tests entailed 1) three normal tidal volume breaths, 2) 
maximal inhalation, 3) forced maximal exhalation, and 4) maximal inhalation. Each 
subject performed three acceptable spirograms. Reported values include forced vital 
capacity (FVC), forced expiratory volume in one second (FEV1), forced mid expiratory 
flow rate (FEF25-75%), and peak expiratory flow rate (PEF).  Maximal voluntary 
ventilation (MVV) was calculated as the maximum amount of air the subject exhaled in a 
12 second period reported as a minute value. Pulmonary function volumes and flow 
measurements are corrected to body temperature and pressure saturated (BTPS). 
Reported lung volumes include total lung capacity (TLC), functional residual capacity 
(FRC), and residual volume. 
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Peak Aerobic Capacity  
Subjects performed an incremental exercise test on an electronically braked, 
computer driven cycle ergometer (Lode Excalibur, Groningen, The Netherlands) to 
measure maximal oxygen consumption. Subjects were initially fitted to the ergometer. 
The ergometer measurements were recorded to ensure consistent cycling position across 
all trials. Subjects were then given verbal and written descriptions of the RPE, RPB, 
rating of perceived unpleasantness (RPU) and leg pain scales. Written instructions were 
provided to the subjects for them to review prior to starting the exercise bout. The 
subjects were instructed to point at the number on the scale at predetermined points 
during each test. The number was verbally repeated to ensure the proper value was 
recorded. Subjects performed a 10-minute warm up, at a self-selected power output. The 
test protocol was explained to the subjects and further questions were answered.  The 
mask was fitted to the subject. After a six-minute rest period, the researcher instructed the 
subject to begin pedaling. Subjects started at 150 watts and each 1-minute stage increased 
by 30 watts until volitional fatigue. Participants were instructed to keep their cadence 
above 70 revolutions per minute (RPM) for the duration of the test. RPE, RPB, RPU, and 
leg pain were collected during the last 20 seconds of each stage. Peak oxygen uptake was 
determined by a RER value greater than 1.15, a heart rate within 10 beats of the age-
predicted maximal heart rate, and a plateau in heart rate and oxygen consumption (<150 
ml·min-1) with an increase in workload (Howley, et al 1995). Subjects were required to 
meet at least two of the three criteria to be considered a valid V̇O2peak test. 
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Protocol Familiarization 
A familiarization trial was implemented to provide an opportunity for the subjects 
to practice rating perceptual responses during exercise and inspiratory capacity 
maneuvers. This trial consisted of the subjects completing a fixed amount of work 
requiring cyclists to cycle for a duration similar to the time required to complete 20-km. 
The subjects were instructed to abstain from eating two hours prior to reporting to 
the laboratory. They were instructed to refrain from caffeine for 12 hours and strenuous 
exercise for 24 hours. These instructions were given in order to replicate the setting 
during the experimental trials. A 24-hour health history and caffeine recall were 
completed prior to testing. The subjects also completed a three-day food and training log. 
They were instructed to eat the same diet during the 24-hour period prior to each time 
trial.   
Fixed-Work Time Trials  
Upon arrival to the laboratory on the experimental visits, subjects were given a 
placebo (gluten free, white flour) or caffeine capsule (5 mg·kg-1 BW). This dosage of 
caffeine is considered moderate and equivalent to approximately 2-3 cups of coffee, 
assuming 100 mg of caffeine per cup (Graham, 2001). After ingestion, the subjects sat 
quietly for 60 minutes to allow for estimated peak blood caffeine concentrations to be 
reached (Graham, 2001). Resting lactate was measured via a finger prick (Lactate Plus, 
Nova Biomedical, Waltham, MA), prior to the start of the time trial. Subjects performed a 
10-minute warm up, at a self-selected power. The test protocol was explained to the 
subjects and further questions were answered. The mask was fitted to the subject. After a 
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brief six rest period while sitting on the bike, subjects began pedaling. Subjects were 
instructed to perform the fixed work time trial as fast as possible.  
Previous research has shown trained cyclists averaged 70-77% of the power 
achieved at V̇O2peak and completed a 20-km TT in 28-34 minutes (Tucker, 2007; Palmer, 
1998). Using these parameters for power and time (75% of peak power and 1800 
seconds), subjects were given a fixed amount of work to complete in an effort to simulate 
a 20-km time trial.  They were instructed to follow the same directions given to them 
during the familiarization trial. RPE, RPU, RPB, and leg pain were collected every 10% 
of the distance completed. Lactate was measured again at 50% and immediately upon 
completion of the time trial. Subjects breathed through a low resistance, two-way valve 
(2700 Hans Rudpolph, Shawnee, KS). Expired respiratory gas exchange was analyzed 
continuously by an automated metabolic cart (ParvoMedics True One 2400, Sandy, 
Utah), and heart rate was recorded telemetrically (Polar, Kempele, Finland). The 
experimental trials were completed within two weeks of each other.  
 
Metabolic, Ventilatory and Perceptual Responses 
Metabolic and ventilatory variables were continuously measured at rest and during all 
whole-body exercise tests using open flow, indirect calorimetry. Prior to each test, the 
metabolic cart and CO2 analyzer were calibrated with room air and a gas of known 
composition in the physiological range (approximately 16% O2 and 4% CO2).  Metabolic 
data were measured over 5-s intervals throughout each time trial. Expired fraction of CO2 
(FeCO2) was continuously measured from a mouthport using a second CO2 analyzer 
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(VacuMed, 17630, Ventura CA) and was converted to yield PETCO2. Pressure generated 
at the mouth was continuously measured from a second mouthport using a differential 
pressure transducer (Validyne MP45, Northridge CA). SpO2 was estimated using a pulse 
oximeter with optodes placed on the forehead (Nellcor OxiMax, Pleasanton, CA). Data 
was averaged at the conclusion at each 10% interval of the time trial using the preceding 
15 second data. V̇O2 and V̇CO2 were corrected to standard temperature pressure dry 
(STPD) conditions. RPE, RPB, RPU, and leg pain were collected at end of every 10% 
interval during the familiarization and experimental time trials.  
 
Statistical Analysis  
 Descriptive statistics were determined for age, height, weight and body mass 
index (BMI) of the participants. Time to completion and average power over the entire 
time trial were compared using a paired t-test. A series of two-way analyses of variances 
(ANOVAs) for repeated measures on two factors (condition (2) and interval (10)) were 
used to examine the perceptual, ventilatory, metabolic and mechanical data. Significant 
main effects were further analyzed using paired t-test and the Bonferroni adjustment for 
the number of pairwise comparisons was employed. Statistical significance was set at the 
0.05 alpha level, apart from the Bonferroni analyses. Subject characteristics, pulmonary 
function, peak VO2, resting data prior to each time and exercise performance data are 
expressed as mean ± SD in tables and mean ± SEM in the figures.  
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Chapter 4 
Results 
 
Subject Characteristics 
A total of sixteen subjects consented to participate in the study. Subjects were 
excluded as follows: five subjects did not meet study qualifications for V̇O2peak, one 
subject presented below normal lung function and one subject withdrew from testing. 
Nine (n=9) subjects completed all visits of the study and were included in subsequent 
analyses. Anthropometric data for subjects are displayed in Table 1. All subjects had no 
history of smoking. Subjects were involved in cycling training at the time of the 
investigation and completed 8.6 ± 3.8 hours of cycling per week at study entry. Subjects’ 
primary cycling disciplines included road (n=5), cyclcocross (n=2) and mountain (n=2).  
      
Table 1. Characteristics of study participants. 
Age Ht Wt BMI 
(yr) (cm) (kg) (kg·m-2) 
34.0 ± 11.3 181.4 ± 6.9 74.4 ± 10.9 22.5 ± 2.1 
Values are mean ± SD. Ht, height; Wt, weight; BMI, 
body mass index 
 
 
Pulmonary Function 
All subjects presented pulmonary function values above the lower limits of 
normal according the prediction equations set forth by ATS/ERS (European and Society 
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2002) (Table 2). Additionally, subjects’ lung volumes were within the predicted normal 
ranges (Table 3).  
Table 2. Spirometry results of study subjects. 
  Measured % pred 
FVC (L)    5.89 ± 1.0  106 ± 12 
FEV1 (L)   4.77 ± 0.7 107 ± 11 
FEV1/FVC (%)   81.5 ± 8.3 100 ± 9 
PEF (L∙s-1)   10.5 ± 1.5 101 ± 13 
FEF25-75% (L∙s-1)  5.02 ± 1.9 119 ± 49 
MVV (L∙min-1)  199.8 ± 31.1 114 ± 19 
Values are mean ± SD. FVC, forced vital capacity; 
FEV1, forced expiratory volume in 1 sec; PEF, peak 
expiratory flow; FEF25-75%, mid-expiratory flow rates; 
MVV, maximal voluntary ventilation 
 
 
Table 3. Lung volumes of study subjects 
TLC (L) FRC (L) FRC (%TLC) RV (L) RV (%TLC) 
%pred %pred %pred %pred %pred 
8.25 ± 1.31 4.19 ± 0.74 51.0 ± 6.1 2.31 ± 0.8 27.5 ± 7.5 
113 ± 14 100 ± 15 100 ± 15 113 ± 32 97 ± 20 
Values are mean ± SD. TLC, total lung capacity; FRC, functional residual capacity; RV, 
residual volume. 
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Peak Aerobic Capacity  
V̇O2peak values for subjects averaged 60.5 ± 5.8 mL·kg-1·min-1, maximal power 
was 387 ± 59 W, and maximal V̇E was 167 ± 32 L·min-1. Additional data from the 
V̇O2peak test are displayed in Table 4. 
Table 4  Metabolic data at maximal exercise 
V̇O2  (L·min-1) 4.23 0.91 
V̇CO2  (L·min-1) 4.83 ± 0.91 
HR (beats·min-1) 169 ± 15 
RER 1.15 ± 0.10 
V̇E/V̇O2  39.6 ± 3.88 
V̇E/V̇CO2 34.6 ± 2.68 
fB (breaths·min-1) 53.1 ± 12.3 
VT (L) 3.31 ± 0.69 
Values are mean ± SD. V̇O2, volume of 
oxygen; VCO2, volume of carbon dioxide; HR. 
heart rate; RER, respiratory exchange ratio;    
V̇E/V̇O2, ventilatory equivalent for oxygen;    
V̇E/V̇CO2, ventilatory equivalent for carbon 
dioxide; fB, breathing frequency; VT, tidal 
volume 
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Time Trials 
There were no differences in any of the metabolic and ventilatory measurements at rest 
when compared with TTPLA and TTCAF.  
Table 5.  Resting data before each TT 
  TTPLA TTCAF 
HR (beats·min-1) 67 ± 12 70 ± 14 
VO2 (mL·kg-1·min-1) 4.38 ± 1.22 4.96 ± 1.74 
VE (L·min-1) 17.1 ± 3.2 19.6 ± 8.0 
VT (L) 1.14 ± 0.21 1.25 ± 0.33 
fB (breaths·min-1) 16 ± 13 15 ± 5 
EELV (%TLC) 61.2 ± 7.5 59.9 ± 7.2 
EILV (%TLC) 74.6 ± 8.3 75.7 ± 7.7 
|IntPm|(cmH2O∙s·min-1) 20.7 ± 5.3 20.9 ± 3.39 
Values are mean ± SD. HR, heart rate; V̇O2, volume of 
oxygen; VE, ventilation; VT, tidal volume; fB, breathing 
frequency; EELV, end expiratory lung volume; TLC, total 
lung capacity; EILV, end inspiratory lung volume; |IntPm|, 
integrated mouth pressure during inspiration 
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Time-to-completion during TTCAF was significantly lower compared with TTPLA 
(p < 0.01). Additionally, the mean power output was significantly greater during the 
TTCAF compared with TTPLA (p < 0.05).  
 
Table 6. Time trial performance results 
  
Time-to-Completion Mean Power 
(min:sec) (W) 
TTCAF 33:22 ± 2:43* 261 ± 51** 
TTPLA 34:57 ± 2:35 250 ± 48 
Values are mean ± SD. Significance between TTCAF and 
TTPLA noted at p < 0.01* and p < 0.05** 
 
All subjects completed TTCAF (0.41 – 2.63 min) faster when comparing to TTPLA as 
depicted in Figure 5-1.  
 
 
Figure 5-1. Time-to-completion during TTPLA and TTCAF (p < 0.01).   
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All but one subject operated at an overall higher power output (-6.8 to 23.41 W) as 
depicted in Figure 5-2.  
 
Figure 5-2. Power outputs during TTPLA and TTCAF (p < 0.05). 
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No condition by interval interaction [F (10, 80) = 0.848, p = 0.584] was detected 
for RPB. Furthermore, RPB was unaffected by caffeine ingestion [F (1, 8) = 0.104, p = 
0.755)].  
 
Figure 5-3. Rating of perceived breathlessness (RPB) during TTPLA and TTCAF (mean ± 
SEM; main effect of condition p=0.755).  
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No condition by interval interaction [F (10, 80) = 1.580, p = 0.128] was detected 
for RPU. Furthermore, RPU was unaffected by caffeine ingestion [F (1, 8) = 0.796, p = 
0.398].  
 
 
Figure 5-4. Rating of perceived unpleasantness (RPU) during TTPLA and TTCAF (mean ± 
SEM; main effect of condition p=0.398).  
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A condition by interval interaction [F (9, 72) = 2.34, p = 0.022] was detected for 
V̇E. Furthermore, minute ventilation was affected by caffeine ingestion [F (1, 8) = 8.65, p 
= 0.019]. Examination of simple main effects revealed no statistical differences in 
ventilation between caffeine and placebo trials at any given interval (Cohen’s d = 0.54-
0.80 at 20-50% of time trial completion).  
 
Figure 5-5. Minute ventilation (V̇E) during TTPLA and TTCAF (mean ± SEM; main effect 
of condition p = 0.019).  
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No condition by interval interaction [F (9, 72) = 0.339, p = 0.959] was detected 
for fB. However, there was a main effect of caffeine on breathing frequency [F (1, 8) = 
7.12, p = 0.028].  
 
Figure 5-6. Breathing frequency (fB) during TTPLA and TTCAF (mean ± SEM; main effect 
of condition p = 0.028).   
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A condition by interval was detected for VT [F (9, 72) = 2.86, p = 0.006]. 
However, there was no overall main effect of caffeine on tidal volume. [F (1, 8) = 3.16, p 
= 0.113]. There was a significant simple main effect only at 40% (p = 0.008).  
 
Figure 5-7. Tidal volume (VT) during TTPLA and TTCAF (mean ± SEM; main effect of 
condition p=0.113).  *Significant difference between TTPLA and TTCAF at the same 
interval (p < 0.05). 
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No condition by interval interaction was detected for IntPm [F (9, 63) = 1.72, p = 
0.103]. However, there was a main effect observed in IntPm [F (1, 7) = 6.30, p = 0.040].   
 
Figure 5-8. Integrated inspiratory mouth pressure (IntPm) during TTPLA and TTCAF (mean 
± SEM; main effect of condition p = 0.113).   
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No condition by interval interaction was detected for end expiratory lung volume 
expressed as a percentage of total lung capacity (EELV %TLC) [F (9, 63) = 0.995, p = 
0.454]. Furthermore, EELV was unaffected by caffeine [F (1, 7) = 0.977, p = 0.356]. 
 
Figure 5-9. End expiratory lung volume expressed as a percentage of total lung capacity 
during TTPLA and TTCAF (mean ± SEM; main effect of condition p = 0.356). It must be 
noted that one subject was not included in the analysis of lung volumes due to his 
inability to correctly perform inspiratory capacity maneuvers.   
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No condition by interval interaction was detected for end inspiratory lung volume 
expressed as a percentage of total lung capacity (EILV %TLC) [F (9, 63) = 1.276, p = 
0.267]. Furthermore, EILV was unaffected by caffeine [F (1, 7) = 2.483, p = 0.159].  
 
Figure 5-10. End inspiratory lung volume expressed as a percentage of total lung 
capacity during TTPLA and TTCAF (mean ± SEM; main effect of condition p = 0.267). It 
must be noted that one subject was not included in the analysis of lung volumes due to 
his inability to correctly perform inspiratory capacity maneuvers.   
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No condition by interaction was detected for V̇E/V̇O2 [F (10, 80) = 1.45, p = 
0.173]. Furthermore, V̇E/V̇O2 was unaffected by caffeine ingestion [F (1, 8) = 1.39, p = 
0.272)].  
 
Figure 5-11. Ventilatory equivalent for oxygen (V̇E/V̇O2) during TTPLA and TTCAF (mean 
± SEM; main effect of condition p = 0.272).   
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No condition by interval interaction was detected for VE/V̇CO2 [F (10, 80) = 1.86, 
p = 0.063). VE/V̇CO2 was unaffected by caffeine ingestion [F (1, 8) = 0.709, p = 0.424)].  
 
 
Figure 5-12. Ventilatory equivalent for carbon dioxide (V̇E/V̇CO2) during TTPLA and 
TTCAF (mean ± SEM; main effect of condition p = 0.424).   
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No condition by interval interaction was detected for PETCO2 [F (10, 80) = 0.584, 
p = 0.823]. Furthermore, PETCO2 was unaffected by caffeine ingestion [F (1, 8) = 0.527, 
p = 0.489)].  
 
 
Figure 5-13. End-tidal carbon dioxide (PETCO2) during TTPLA and TTCAF (mean ± SEM; 
main effect of condition p = 0.489).   
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No condition by interval interaction was detected for RPE [F (10, 80) = 0.823, p = 
0.607]. Furthermore, RPE was unaffected by caffeine ingestion [F (1, 8) = 0.280, p = 
0.611]. 
 
Figure 5-14. Ratings of perceived exertion (RPE) during TTPLA and TTCAF  (mean ± 
SEM; main effect of condition p = 0.611).   
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No condition by interval interaction was detected for leg pain [F (10, 80) = 0.844, 
p = 0.588]. Furthermore, leg pain was unaffected by caffeine ingestion [F (1, 8) = 0.533, 
p = 0.486]. 
 
Figure 5-15. Leg pain during TTPLA and TTCAF (mean ± SEM; main effect of condition p 
= 0.486).   
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No condition by interval interaction was detected for V̇O2 expressed as a 
percentage of peak [F (9, 72) = 0.993, p = 0.453]. However, there was a main effect of 
caffeine on oxygen consumption [F (1, 8) = 17.473, p = 0.003].   
 
Figure 5-16. Oxygen consumption as a percentage of peak (V̇O2 %peak) during TTPLA 
and TTCAF (mean ± SEM; main effect of condition p = 0.003).  
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No condition by interval interaction was detected for power expressed as a 
percentage of peak [F (9, 72) = 0.786, p = 0.630]. Furthermore, power expressed as a 
percentage of peak was unaffected by caffeine ingestion [F (1, 8) = 2.04, p = 0.191].  
 
Figure 5-17. Power expressed as a percentage of peak (poweravg (%peak)) during TTPLA 
and TTCAF (mean ± SEM; main effect of condition p=0.191)  
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Power was determined by two different methods. Instantaneous power was 
averaged during the 15-20 seconds prior to interval completion. Power was the average to 
complete each interval.  No condition by interval interaction was detected for 
instantaneous power [F (9, 72) = 1.40, p = 0.204). However, there was a main effect 
observed in instantaneous power [F (1, 8) = 8.43, p = 0.020)].  
 
Figure 5-18. Instantaneous power during TTPLA and TTCAF (mean ± SEM; main effect of 
condition p = 0.191) *Significant difference between TTPLA and TTCAF at the same 
interval (p < 0.05). 
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No condition by interval interaction was detected for power [F (9, 72) = 0.331, p 
= 0.962]. However, there was a main effect observed in power during caffeine trial when 
compared to the placebo trial [F (1, 8) = 6.75, p = 0.032].  
 
 
Figure 5-19. Power output during TTPLA and TTCAF (mean ± SEM; *significant main 
effect of caffeine versus placebo on power throughout the time trial p = 0.032) 
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There was a main effect observed in heart rate during the caffeine trial when 
compared to the placebo trial [F (1,7)=12.835, p = 0.009] and condition by interval 
interaction [F (9,63) = 3.127, p = 0.004). There were significant simple main effects at 
30%, 40%, and 60% of completion during TTCAF when compared to TTPLA.  
 
 
Figure 5-20. Heart rate during TTPLA and TTCAF (mean ± SEM; main effect of condition 
p=0.009)  *Significant difference between TTPLA and TTCAF at the same interval (p < 
0.05). 
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No condition by interval interaction was detected for respiratory exchange ratio 
(RER) [F (10, 80) = 1.827, p = 0.069]. Furthermore, RER was unaffected by caffeine 
ingestion [F (1, 8) = 2.629, p = 0.144].  
 
Figure 5-21. Respiratory exchange ratio (RER) during TTPLA and TTCAF (mean ± SEM; 
main effect of condition p=0.144) 
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No condition by interval interaction was detected for lactate [F (2, 10) = 3.11, p = 
0.089]. There was a main effect observed in lactate after caffeine ingestion [F (1, 5) = 
8.651, p = 0.032].  
 
 
Figure 5-22. Lactate during TTPLA and TTCAF (mean ± SEM; main effect of condition p = 
0.032). It should be noted two subjects were not included in the analysis of lactate due to 
insufficient assistance needed to perform lactate measurements. 
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Chapter 5 
Discussion  
The purpose of this study was to examine exercise performance and perceptual 
responses in well-trained, male cyclists at self-selected work rates during fixed work 
exercise with and without the consumption of caffeine. To our knowledge, this is the first 
study to examine perceptual responses in conjunction with ventilatory mechanics to 
determine their contribution to caffeine’s ergogenic effect on exercise performance.  
Caffeine significantly decreased time-to-completion. This was accomplished 
through a significant increase in the average power maintained throughout the TT. These 
data support our hypothesis that caffeine enhances exercise performance. No differences 
existed in RPB and RPU between TTCAF and TTPLA, which supported our hypotheses. 
However, contrary to our hypotheses, RPE and leg pain did not differ between 
conditions. Thus, subjects cycled at a higher power output without alteration of their 
perceptual responses, indicating caffeine may increase the threshold at which individuals 
experience breathlessness.  
All subjects who participated were young, healthy individuals with a normal 
weight and BMI. Their medical histories were absent of any cardiovascular, metabolic, or 
renal diseases that would alter their performance. All subjects were habitual caffeine 
users and consumed approximately 100-300 mg of caffeine daily in the form of tea or 
coffee. At enrollment into the study, all subjects were training for their respective 
competition disciplines.  
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Pulmonary Function 
All subjects had normal pulmonary function based on their age, height, and sex. 
Pulmonary function of all subjects was above the lower limits of normal with nearly all 
mean values reaching above 90% of predicted. All pulmonary function data were 
collected according to ATS/ERS guidelines with well-established and well-maintained 
equipment to ensure precise measurements.  
Time Trial Protocol  
The subjects were trained cyclists, thus 20-km is not an unfamiliar distance. 
However, not all of the subjects had specifically completed a fixed work time trial 
equivalent to 20-km before. This distance is applicable to the cycling field, as it is the 
distance used in the bike portion of a Sprint Triathlon.  
No differences between conditions were observed for HR, V̇O2, V̇E, fB, VT or 
IntPm at rest. Bell et al. (1999) reported no differences in resting V̇O2, V̇CO2, V̇E, HR, 
and RER after caffeine ingestion (6 mg·kg-1 BW) in moderately trained individuals 
(V̇O2max = 51 ± 8 ml·kg-1). Contrary, Powers et al., (1986) reported a significant 
difference in resting V̇E, HR and V̇CO2 after a dose of 7 mg·kg-1 BW of caffeine in 
moderately trained individuals (V̇O2max = 53 ± 1 ml·kg-1). Differences in the caffeine 
dose utilized between investigations may account for the differences observed in 
parameters measured at rest. Further, in regards to the current study, there may have been 
a residual effect of the warm up period on the resting data. All subjects completed a 10-
minute warm up at a self-selected pace. Within 1-2 minutes after the warm up was 
completed, the mask was fitted on the subjects and the six-minute resting period was 
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initiated. A longer resting period (e.g., 10 minutes) may be needed to measure significant 
differences in ventilation or heart rate between conditions.  
Exercise Performance 
 Time-to-completion significantly decreased during TTCAF compared with TTPLA, 
which equated to an approximately 4% increase in performance. This magnitude of 
improvement is meaningful to athletes. Average power output over the entire time trial 
was significantly increased during TTCAF, which equated to an approximately 3% 
increase. All but one subject operated at a higher power output during the caffeine trial. 
None of the subjects performed slower during TTCAF. Guest (2018) reported significant 
increases in endurance performance during a 10-km TT for fast metabolizers of caffeine 
who have the CYP1A2 AA genotype. Subjects who were AC genotype or CC genotype 
were considered slow metabolizers and had impaired performance or no effect on 
performance. This may be a reason why one subject did not operate at a higher power 
output during the caffeine trial. However, determining if our subjects were fast or slow 
caffeine metabolizers was beyond the scope of this study.  
McNaughton et al. (2008) observed a 6% increase in performance during a 20-km 
time trial after caffeine ingestion (6 mg·kg-1 BW). However, uphill stretches were 
included in the protocol, which altered their pacing strategies. Bortolotti et al., (2014) 
reported that caffeine ingestion (6 mg·kg-1 BW) did not significantly improve the 
performance of cyclists in a 20-km TT. There was an insignificant improvement of 
0.46% (~10 seconds) during the caffeine trial. The researchers were unable to explain 
why caffeine consumption did not improve performance in their study. However, there 
was a difference in the training status of subjects between studies: Bortolotti et al.,  
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(2014) used moderately trained individuals (peak power: 345± 41 W) , while 
McNaughton et al., (2008) used well trained subjects (63.6 ± 4.4 mL·kg·min-1). Our data 
are supported by the findings of McNaughton et al., (2008) whose subjects fitness level 
are more similar to the subjects used in this study. 
The subjects in this study were considered well-trained individuals according to 
their V̇O2peak values. Previous studies examining the effect of caffeine on performance in 
trained cyclists had subjects with average V̇O2max of 57.5 ± 4.6 mL·kg-1·min-1 
(Cordingely 2016), 57.5 ± 3.9 mL·kg-1·min-1 (Astorino et al., 2012b), 56.9 ± 6.6, and 66.4 
± 8.7 mL·kg-1·min-1  (Smolka and Kumstate, 2014). Astorino et al., (2012b) examined 
caffeine’s effect on RPE, perceptions of pain and arousal, please and displeasure in 
endurance trained and active men during a 10-km cycling time trial. Cycling performance 
significantly increased only in the trained men. However, mood significantly increased 
only in the active men. Smolka and Kumstat (2014) reported that caffeine significantly 
increased power output in sub-elite (V̇O2max of 56.9 ± 6.6 mL·kg-1·min-1; training 
volume: 10-15 hours·week) cyclists but not in elite cyclists (V̇O2max of 66.4 ± 8.7 mL·kg-
1·min-1, training volume: 30-35 hours·week). This may further reiterate the fact that it is 
difficult for elite athletes   to make significant improvements in their fitness once they 
reach the ceiling of their athletic potential. The subjects in our study were considered 
well-trained, but not elite, and thus caffeine elicited a significant ergogenic effect.  In a 
study with well-trained cyclists of similar fitness status (V̇O2max 65.0 ± 6.3 
mL·kg−1·min−1) and caffeine ingestion (6 mg·kg-1 BW) McNaughton et al., (2008) 
concluded that cycling performance was improved significantly.  
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Perceptual Responses 
To our knowledge, only one other study has examined RPB after caffeine 
ingestion in trained individuals (Hadjicharalambous et al., 2006). Their results indicate 
RPB was significantly lower after caffeine ingestion during a constant-load exercise on a 
cycle ergometer.  Killen et al., (2013) examined session RPE along with RPB after 
caffeine ingestion (6 mg·kg-1 BW) in active men and women during a constant-load 
exercise on a cycle ergometer. Results indicate RPB was significantly lower, which is in 
agreement with Hadjicharalambous et al. (2006). These studies (Hadjicharalambous et 
al., 2006; Killen et al., 2013) indicate that caffeine lowers the RPE and RPB when 
cycling at constant power.  
Subjects reported RPB and RPU to be the same between TTCAF and TTPLA. There 
was a main effect of caffeine on V̇E during TTCAF compared with TTPLA. The increased 
power output and ventilation would be expected to elevate the perceptual responses. 
Increased fB, rather than increased VT, resulted in an increase in V̇E. This indicates 
subjects were implementing a ventilatory strategy that is more efficient with respect to 
respiratory muscle energetics. However, V̇E didn’t necessarily increase due to the direct 
effects of caffeine. V̇E increased due to subjects operating at a higher power output, 
resulting in a higher demand for oxygen needed by the working skeletal muscles. Thus, a 
higher CO2 production, which ultimately stimulates ventilation. There were no 
differences in VE/V̇O2, VE/V̇CO2, or PetCO2, which would indicate that caffeine was 
increasing ventilation in proportion to metabolic demands.  
Further, IntPm, an index of work of breathing, was significantly increased during 
TTCAF when compared with TTPLA . However, caffeine may act on adenosine receptors in 
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the respiratory muscles through the same mechanism as it does on adenosine receptors 
throughout the body to help attenuate leg pain or RPE. Supinksi (1986) demonstrated that 
a dose of 600 mg of caffeine enhances inspiratory muscle endurance while decreasing the 
sense of effort associated with respiratory muscle fatigue. Caffeine’s effect on the central 
nervous system may result in a decrease of outflow from the central respiratory motor 
neuron pool, which would ultimately decrease the inspiratory muscle pressure during 
fatiguing exercise. This would ultimately result in a decrease in work of breathing and a 
decrease in the perception of breathlessness. IntPm was significantly increased in this 
current study, however, effort of breathing stayed the same during both TT’s. Respiratory 
drive was not necessarily measured in this study. However, it can be assumed there was 
an increase in respiratory drive during TTCAF as evidenced by the increases in V̇E and 
IntPm.    
In the current study, there was a minimal effect of caffeine on VT (VT was 
significantly increased during the caffeine trial only at 40%).  EILV stayed relatively the 
same (approximately 90% TLC) in all subjects in both TT’s. Additionally, EELV was not 
different between conditions at any interval. These insignificant changes seen in 
operational lung volumes resulted in the insignificant changes seen in tidal volume. 
During exercise, operational lung volumes (i.e., EILV and EELV) operate under precise 
control but are dynamic in nature, which is advantageous during exercise. In healthy 
individuals, there is an increase in EILV and a decrease in EELV during exercise 
compared with at rest. EELV will continue to decrease with increasing exercise intensity, 
to a certain point, and then will increase back to resting levels (Henke et al., 1988). This 
mechanism (or strategy) is considered more advantageous due to the optimal length or 
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position of the respiratory muscles, which helps decrease the work of breathing (Henke et 
al., 1988). This is a regulated system between respiratory effort and mechanical responses 
within the respiratory system. When tidal volume occurs at higher lung volumes, there is 
an increase in the work of breathing due to a decrease in lung compliance. A greater 
amount of pressure is needed to inspire but not necessarily expire. If the inspiratory 
muscles are also operating at a shorter length, due to operating at a higher lung volume, 
this may contribute to respiratory muscle fatigue, as the respiratory muscles are operating 
closer to their maximal force generating capacity. Previous research has shown that 
EELV decreases during exercise in men, which is contrary to the results seen in this study 
(Henke et al., 1988; Johnson et al., 1999; Guenette et al., 2007; Mota et al., 1999). 
However, EELV can increase with heavy exercise. From rest to completion of the time 
trials, in this current study, EELV gradually trended upwards. 
Central chemoreceptors located within the medulla and peripheral chemoreceptors 
located in the carotid artery are important for controlling ventilation (Power & Howley, 
2012). Carbon dioxide is a powerful stimulant of ventilation. There was a gradual 
decrease in PetCO2 during both TT’s, however the pattern of change did not differ 
between the TT’s.  
RPE and leg pain have been widely studied in a variety of populations such as 
elite male athletes, trained women, nonathletic women, and sedentary men (Astorino et 
al., 2012b; Anderson et al., 2000; Astorino et al., 2012c; Wallman et al., 2010; Engels 
and Haymes, 1992). RPB, RPU, RPE and leg pain did not differ between conditions in 
this current study. Previous research has shown RPE to be lower during caffeine trials 
compared to placebo trials during constant-load exercise (Motl et al., 2006; Gliotttoni, 
 
 
59 
2009; Backhouse et al., 2011; Doherty and Smith, 2005). Contrarily, there are published 
reports indicating that caffeine does not alter RPE or leg pain during exhaustive exercise 
(Astorino et al., 2012c; Cordingley et al., 2016). 
Mechanical and Metabolic Work  
 Oxygen consumption during TTCAF was significantly greater compared with 
TTPLA. Subjects were operating at a higher power output during TTCAF so their working 
skeletal muscles and heart were utilizing more oxygen to perform the increased work 
rate. This also led to the significant increases in heart rate. There were no condition by 
interval interactions for power output, however there was a significant main effect. This 
is indicative of operating at a higher power output while maintaining a similar pacing 
strategy between trials.  
Ivy et al., (1979a) examined performance during two hours of isokinetic cycling 
after ingestion of 250 mg of caffeine. Oxygen consumption was significantly increased 
during the caffeine trial, which supports the results from this current study. Total work 
performed was also significantly increased during the caffeine trial. During the first 50 
minutes of the caffeine trial conducted by Ivy et al., (1979a), there was no shift of 
substrate utilization, as determined by the RER. This also supports this current study, as 
there was no significant difference in substrate utilization as measured by RER. However, 
during the last 60 minutes of the caffeine trial, Ivy et al., (1979a) reported significantly 
higher fat oxidation. Since publication of the study by Ivy et al., (1979a), there has been a 
plethora of studies indicating that caffeine does not decrease RER and/or increase plasma 
free fatty acids during vigorous exercise (Glaister et al., 2016b; Talanian and Spriet, 
2016; Jenkins et al., 2008; Tarnpolsky, 1989; Graham & Spriet, 1991; Spriet, 1992). 
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 Lactate was significantly increased during TTCAF when compared to TTPLA. 
Subjects were operating at a higher power output and a higher percentage of their 
VȮ2peak, indicating a greater reliance on anaerobic metabolism. Research examining 
caffeine and lactate primarily use incremental exercise protocols, which makes it difficult 
to compare the results of this current study to previously published studies. However, it 
should be noted that the gold standard for measuring lactate is to obtain an arterial blood 
sample rather than a capillary sample, which was the method used in this current study. 
Blood lactate measurements can be taken intravenously, directly into a syringe, or from a 
finger “stick” drawn into capillary tubes and then mixed (Nordstrom, 1998). Portable 
lactate analyzers are now available, which use a blood sample from a finger or earlobe 
stick. When using the finger stick for a blood sample, one may have to “milk” the finger 
to get an adequate sample. This may cause interstitial fluid to be introduced into the 
sample, thus diluting the sample (Hart et al., 2013). This may contribute to varying 
lactate measures obtained. The reliability and accuracy of the device used in this study 
may have masked the condition by interval differences in blood lactate response as well.  
Limitations 
The small sample size may be the main limitation of this study. Many of the 
variables have large effect sizes but no statistically significant differences, indicating a 
larger sample size is needed. Subjects were required to wear the mask for the entire 
duration of the TT’s. Subjects could have reported perceptual responses that also 
accounted for the discomfort the mask. Almost all of the subjects reported the mask 
hindered their ability to perform the time trials and if they didn’t wear the mask, their 
performance would have been improved. Waiting 60 minutes may not have been the 
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optimal time for all subjects to wait prior to starting the time trial. Research has shown 
caffeine reaches a peak blood concentration 30-180 minutes after ingestion (Graham, 
2001). There are also slow and fast metabolizers of caffeine, which is determined by a 
single nucleotide polymorphism on the cytochrome of the P450 gene (Guest, 2018). 
Determining is subjects were slow or fast metabolizers was out of the scope for this 
study.  
Conclusion 
In conclusion, the consumption of a moderate dose of caffeine results in enhanced 
exercise performance in trained cyclists. Improved exercise performance was 
accompanied by increases in ventilatory work and O2 utilization. Despite these changes 
to physiological parameters, no differences in any perceptual responses were reported 
between conditions. These data indicate caffeine may alter the threshold at which one 
experiences breathlessness, ultimately resulting in an increase in performance.  
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Appendix A.b: Raw Data - Pulmonary Function  
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Appendix A.d: Raw Data - Caffeine Time Trial  
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Appendix A.e: Raw Data - Placebo Time Trial  
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Appendix C: Informed Consent Statement 
 
 
Appalachian State University 
Informed Consent for Participants in 
Research Projects Involving Human Subjects 
 
 
Title of Project: The effect of caffeine on perception of breathlessness during a 
20-km time trial in trained male and female cyclists.  
 
IRB Study #: 17-0302  
  
A. Principal    
Investigator:  Erica Larson, B.S.   Email: larsone@appstate.edu 
     
Advisor:  Andrew Shanely, Ph.D.  Email: 
shanelyra@appstate.edu 
Advisor:  Jonathon Stickford, Ph.D.  Email: 
stickfordjil@appstate.edu  
Advisor:  Kym Fasczewski, Ph.D.  Email: 
fasczewskiks@appstate.edu 
 
Research Assistants: Jayvaughn Oliver, B.S.  Email: oliverjt@appstate.edu 
    
     
 
This is to certify that I,                                                                             have been given the 
following information with respect to my participation as a volunteer in a program of 
investigation under the supervision of Erica Larson B.S. to which Andrew Shanely Ph.D., and 
Jayvaughn Oliver may be assisting. 
 
1. Purpose of the study: 
 Caffeine is a legal, widely used drug which aids in enhancing exercise performance. 
Moderate to high intensity exercise is associated with naturally occurring pain in the 
muscles that are activated. Caffeine can modify pain perception during exercise, leading to 
increases in performance. Increases in exercise intensity will result in increases in 
ventilation. Increases in ventilation can lead to feelings of breathlessness while exercising. 
This study will contribute to how we understand caffeine helps us work harder. 
Discovering another potential way, as to how caffeine can enhance performance, is 
important to athletes who consume caffeine.  
 The purpose of this study is to measure the rate of perceived breathlessness after 
the taking of a moderate dose of caffeine in trained male and female cyclists, while also 
measuring differences in pain perception and performance. 
 
2. Inclusion Criteria: You may participate in the study if the following apply to you: 
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• Sex: Males and Females will be included in the study.  
• Ethnicity: Any. 
• Age: 18 – 50 years of age 
• Interest in participating in the research study. 
• Train as a cyclist by riding a bicycle for at least three hours per week. 
• Have a relative VO2max of at least 53ml/kg/min (males), 48ml/kg/min (females). 
• Understand written and oral instructions in English. 
• Provide informed consent. 
• Available during times the data collection is offered. 
• Have normal lung function.  
• Have smoked less than a half a pack of cigarettes per day for one year. 
• If female: 
o Not pregnant or planning on becoming pregnant. 
o Taking oral contraceptives.  
• Consuming < 4 cups of coffee daily.  
 
Exclusion Criteria: You should not participate in this study if any of the following apply 
to you: 
• Known cardiovascular, metabolic or renal disease, or signs/symptoms suggestive of 
cardiovascular, metabolic or renal disease.  
• Train less than 3 hours per week as a cyclist by riding a bicycle.  
• Have a relative VO2max less than 53ml/kg/min (males), 48ml/kg/min (females) 
• Do not have normal lung function.  
• Have smoked more than a half a pack of cigarettes per day for one year. 
• If female: 
o Pregnant or planning on becoming pregnant. 
o Not taking oral contraceptives.  
• Hypersensitive to caffeine, defined below.  
• Consuming >4 cups of coffee daily.  
 
 
3. Procedures: Please read the descriptions of each experimental day and write your initials in 
the space provided.  
 
You could be asked to repeat a trial, procedure, or test. This could happen for many 
reasons such as equipment failure, power outage, inconclusive test results, etc. However, 
you do not have to repeat a trial, procedure, and/or test if you do not wish to do so. 
 
Below is a timeline showing all visits and experiments which you will complete in this study. 
 
Visit 1 Visit 2 Visit 3-4 
Informed Consent 
Medical & Exercise History 
Pulmonary Function Test 
Body Composition 
VO2max test 
 
20-km Familiarization Time Trial 20-km Time Trial 
Caffeine or Placebo 
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________initial      Prescreen: You may be telephoned by the Principle Investigator or a Research 
Assistant (see page 1) and asked screening questions to determine your eligibility for the study. 
 
Visit 1:  
 
________ initial      Consent and Questionnaires: Potential participants who meet inclusion 
criteria will be invited to a screening interview within the laboratory located off campus (Charleston 
Forge Research Site). At this screening visit, the study will be explained in-depth to you by the PI 
or a trained research assistant. You will be provided time to consider your options and get all 
questions answered - if you agree to participate, you will then provide your written informed 
consent. 
 
After you have provided consent (~30 minutes), you will be asked to complete questionnaires: 1) 
a medical history questionnaire (~10 minutes) and 2) an exercise history questionnaire (~10 
minutes). 
 
________ initial      Pulmonary Function Testing (PFT): You will be asked to perform tests of 
breathing function. The protocol will follow that described by the American Thoracic Society. 
These tests include measurement of the total volume of air your lungs can hold, the volume of air 
that you can push out with one maximal breath, the volume of air that you can forcefully breathe 
out in one second, and the maximum volume of air that you can breathe in 12 seconds. For all these 
procedures, you will wear a nose clip and breathe through a disposable mouthpiece. These 
procedures will take ~45 minutes total. 
 
 
_________initial      Body Composition: Following completion of the questionnaires, we will 
measure your height, weight, waist circumference, and body composition. Your percent body fat 
will be measured using a Bod Pod plethysmograph. You will sit in a chamber and may hear some 
clicking while air pressure changes to estimate your body volume. This piece of equipment 
estimates your body’s composition of fat and muscle by air movement. This is accomplished by 
measuring your mass (scale) and body volume (relationship between pressure and volume in 
chamber) and entering it into a calculation for fat mass and fat free mass (muscle). This is an 
extremely accurate method and presents no risk. These procedures will take ~15 minutes total 
 
________ initial      Maximal Aerobic Capacity Exercise Test (V̇O2max): You will be asked to 
perform a maximal exercise test to examine your cardiovascular fitness. This test will measure your 
highest exercise capacity and is often described as a V̇O2max test. You should be rested, well 
nourished, and hydrated for the test and avoid caffeine, and tobacco 3 hours before the test, and 
refrain from alcohol for 12 hours before the test. Avoid significant exertion or exercise the day of 
testing and report any medication that you are using to the testing staff before the test. When you 
are ready to perform the test, the investigators will help with necessary adjustments to testing 
equipment to assure your comfort. You will be fitted with a rubber mouthpiece and nose clip. Your 
breathing pattern, exercise metabolism, exhaled carbon dioxide, and arterial blood oxygen level 
(via pulse oximetry) will be monitored during the test. This procedure will require ~45 minutes 
total, with exercise lasting approximately 15 minutes. 
 
Cycling Protocol 
You will perform cycling exercise on a stationary bicycle. Prior to exercise, you will rest sitting on 
the bike with both hands on the handle bars for 5 minutes. You will breathe through a mouthpiece 
and wear a nose clip during the test. Your breathing pattern, exercise metabolism, exhaled carbon 
dioxide, and arterial blood oxygen level (via pulse oximetry) will be monitored during the test. 
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Pulse oximetry is a method of determining the amount of oxygen in the blood by using a sensor 
placed on the skin (e.g., forehead).  Throughout the test, you will be asked about your perceptual 
responses (e.g., ratings of perceived breathlessness, unpleasantness of breathlessness, perceived 
exertion and leg muscle pain) to the exercise. You will be asked to rate your breathing by pointing 
with your finger to a number on a scale, which will represent your perceived level of breathlessness. 
The number will be repeated out loud in order to confirm your choice. During the exercise you may 
have an even stronger or greater intensity of breathlessness than you have previously experienced. 
If this occurs, you should point to the word “maximal” if the severity is greater than 10. After the 
mouthpiece is removed, you can tell us the number. A small blood sample (a few drops) for blood 
lactate will be obtained by sticking your finger. You may stop exercise when you wish, because of 
personal feelings of fatigue or discomfort. Following completion of the test, you will perform a 
light intensity cool-down. 
 
 
 
Flow-Volume Loops 
During the maximal exercise test, the speed at which you breathe air in and out and the volume of 
air you breathe will be measured. Approximately once every 60 seconds during the exercise test, 
you will be prompted to breathe in completely, filling your lungs with air, and then return to normal 
breathing. Before and after the exercise test, while at rest, you will be prompted to perform 3 
breathing maneuvers, where you complete a maximal inhalation (filling your lungs completely with 
air) followed by a complete exhalation (breathe out all the air you can). The investigators will coach 
you through these maneuvers. These procedures are performed during the maximal exercise test, 
and add no additional time. 
 
 
Visit 2-4: 
 
________ initial      Nutrition Recall: You will be asked to record all foods and supplementation 
you consume during the three days leading to visits 3 & 4.  
 
________ initial      Caffeine Recall: You will be asked to record all caffeine you consume during 
the 7 days leading to visits 3 & 4. A list of popular items that contain caffeine will be provided for 
you.  
 
________ initial      20km Time Trial: A standardized 10-min warm-up will be allowed before 
each trial. You will complete a 20km time trial under placebo (P) and caffeine (CAF) conditions in 
a random order. You will be given instructions to complete the distance in as fast of a time as 
possible. The same range of gear ratios will be used for each trial and you will be permitted to 
adjust this throughout the trial. The elapsed time will be recorded and used for comparison. A 
minimum of 48 hours will be between visit 2 and 3 and visit 3 and 4.  
 
________ initial    Caffeine Consumption: A dose of 5 mg/kg body weight of caffeine will be 
administered orally to you on one visit. This is approximately equal to two to three cups of coffee. 
Caffeine will be administered orally via a vegan capsule. The placebo will be gluten free flour and 
will also be administered orally via a vegan capsule. 
 
________ initial      Finger Blood Lactate Test: A finger stick will be used to collect a small blood 
sample (a few drops) to measure your blood lactate prior to the start of cycling, halfway during the 
20-km time trial and approximately 5 minutes post completion of each 20k time trial.  
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________ initial   Breathlessness Questionnaire: Following the exercise tests, you will be asked 
to complete a questionnaire about the breathing sensations that you experienced during 
exercise. During this “debriefing session” we will give you a questionnaire including 15 
respiratory sensation descriptors to describe the respiratory sensations you were most often 
experiencing (e.g., respiratory work/effort, air hunger, and/or chest tightness). 
 
3.  Discomforts and risks: 
There are minimal risks involved with measuring/monitoring/performing: questionnaires, 
physical characteristics, body composition, activity assessment, pulmonary function testing, flow-
volume loops, and breathlessness during exercise. 
 
Maximal Aerobic Capacity Exercise Test (VO2max): VO2max test risks include abnormal heart 
beats, abnormal blood pressure responses, muscle cramps, muscle strain and/or joint injury, 
delayed muscle soreness (1 to 2 days afterwards), light headedness, fatigue, and in rare instances, 
heart attack. Men > 45   years old, are at a higher risk for developing cardiovascular disease, 
which include coronary heart disease, heart failure, peripheral vascular disease and stroke. These 
may increase your risk for a cardiovascular event to occur. 
 
Caffeine Consumption: Consuming caffeine may cause symptoms of caffeine hypersensitivity 
that include feelings of nervousness, restlessness, upset stomach, fast heartbeat, and insomnia. If 
any of these symptoms are felt, and the discomfort is too great, you can remove yourself from the 
study. You will be screened prior to entering the study to ensure you are not hypersensitive to 
caffeine. 
 
Finger Blood Lactate Test: Collection of finger blood lactate may cause minimal local pain and 
discomfort. There is a very small risk of infection. If the discomfort is too great, you can refuse to 
provide a blood sample. The sample site will be cleansed with an alcohol swab prior to sample 
collection. A new single-use lancing stick will be used for every sample collected. 
 
Loss of Confidentiality: Any time information is collected; there is a potential risk for loss of 
confidentiality.  Every effort will be made to keep your information confidential; however, this 
cannot be guaranteed.  
 
Other Risks: There may possibly be other side effects that are unknown at this time. If you are 
concerned about other, unknown side effects, please discuss this with the researchers. 
 
How you can help reduce some of the risks:  During your participation in this research, the 
researchers will closely observe your testing to determine whether there are problems that need 
medical care.  It is your responsibility to do the following: 
•  Ask questions about anything you do not understand. 
•  Keep appointments. 
•  Follow the study researchers’ instructions. 
•  Let the researchers know if your telephone number changes. 
•  Tell the researchers before you take any new medication. 
•  Tell your regular doctor about your participation in this research. 
•  If female, inform the researchers if you become pregnant.  
 
 
 
4.    a. Benefits to you: You can expect to receive knowledge of your lung function, 
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cardiovascular conditioning, and cardiovascular fitness. We are performing these tests for 
research purposes only. The information collected is not intended for diagnostic or 
therapeutic purposes. Under no circumstance will the investigator or research staff interpret 
results as normal or abnormal. We are unable to make any medical comments about your 
results. The results will not be looked at for medical diagnostic or medical treatment 
purposes.  
 b. Potential benefits to society: The knowledge gained from this study serves great 
clinical significance regarding how people who consume caffeine may alter their own 
breathing efforts during exercise.   
 
5.  Alternative procedures that could be utilized:  Not participating in the study. 
The procedures used in this study are frequently used in research and are the most appropriate 
methods to accomplish the goals of this research. 
 
 
6. Time duration of the procedures and study:   
 
You will need to visit the Charleston Forge Laboratory for the following: 
________ initial Visit 1 (about 1.5 - 2 hrs) 
________ initial Visit 2 (about 1 hour). 
________ initial Visit 3 (about 2 hours). 
________ initial Visit 4 (about 2 hours). 
 
Approximately 7 hours Total 
 
7. Statement of confidentiality: Volunteers are coded by an identification number for statistical 
analyses. All records are kept in a secure location. All records associated with your 
participation in the study will be subject to the university confidentiality standards and in the 
event of any publication resulting from the research no personally identifiable information will 
be disclosed. The Office of Human Research Protections in the U.S. Department of Health and 
Human Services, the U.S. Food and Drug Administration (FDA), the Office for Research 
Protections at Appalachian State University and the Institutional Review Board may review 
records related to this project. 
 
8. Right to ask questions: Please contact Erica Larson B.S. (larsone@appstate.edu, c. 814-860-
6631) or Andrew Shanely (shanelyra@appstate.edu, 828-262-6319), with questions, 
complaints, or concerns about this research. If you have any questions about your rights as a 
research subject, please contact the IRB Administrator at the Appalachian State University 
Institutional Review Board Office at (828) 262-2692, irb@appstate.edu.  This study has been 
approved on 1/17/2018 by the Institutional Review Board (IRB) at Appalachian State 
University.  This approval will expire on 8/3/2018 unless the IRB renews the approval of this 
research. 
 
9. Compensation: You will receive a total of $42 upon completion of this study:  
Compensation Breakdown: You will receive $21 per experimental protocol completed 
(each of Visits 3 and 4). Total: $42 
 
You may be asked to repeat a trial.  If you agree to repeat a trial, you will be paid for the 
repeated trial as stated above. 
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10. Injury Clause: In the unlikely event you become injured as a result of your participation in 
this study, standard emergency procedures will be followed. If you get hurt or sick when you 
are not at the research site, you should call your doctor or call 911 in an emergency. If your 
illness or injury could be related to the research, tell the doctors or emergency room staff 
about the research study, the name of the Principal Investigator, and provide a copy of this 
consent form if possible. Please contact the PI as soon as possible (Erica Larson B.S. 
larsone@appstate.edu, c. 814-860-6631) or Andrew Shanely (shanelyra@appstate.edu, 828-
262-6319). It is the policy of this institution to provide neither financial compensation nor 
free medical treatment for research-related injury. You will be responsible for any costs for 
medical care not paid by your insurance company. No other compensation is offered by 
Appalachian State University.  By signing this document, you are not waiving any legal 
rights that you have against Appalachian State University for injury resulting from negligence 
of the University or its investigators. 
 
11. Voluntary participation: Your participation in this study is voluntary. You may withdraw 
from this study at any time by informing the research personnel. You may decline to answer 
certain questions and may decide not to comply with certain procedures. However, your being 
in the study may be contingent upon answering these questions or complying with the 
procedures. The researcher may end your role in the study without your consent if the 
researcher deems that your health or behavior adversely affects the study or increases risks to 
you beyond those approved by the Institutional Review Board and agreed upon by you in this 
document. You have been given an opportunity to ask any questions you may have, and all 
such questions or inquiries have been answered to your satisfaction. 
 
____________________________________________________ 
      Volunteer         
 
Date 
 
 
I, the undersigned, have defined and explained the studies involved to the above volunteer. 
 
 
____________________________________________________ 
      Person Obtaining Consent   
 
Date 
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Appendix D: Telephone Screening Form 
 
Initial Telephone Screening Form for Cycling Study 
 
General Information: 
Name: _________________________________________________  
Email: _________________________________________________ 
Address (if no email): _____________________________________ 
Age: _________  Sex: _________       Phone: ________________   
Height: _______  Weight: _______         Allergies (latex?)_________ 
 
Exclusion Criteria: any question answered “yes” in this section will disqualify the 
potential subject. 
 
Yes     No 
 
1.            Age – outside the ages of 18 and 50 yr? 
 
2.            Do you currently smoke tobacco cigarettes? Any   
   history of smoking? If so, how much did you smoke  
  and for how long? (Must be less than 0.5 pack·yrs) 
 
3.            Have you ever been diagnosed with a sleep disorder  
  or use CPAP? 
 
4.            Do you have a history of asthma, COPD, or any lung  
  issues? 
 
5.            Do you have a history of an irregular heartbeat or any  
  heart condition? (Have you had an EKG performed?) 
 
6.         Do you have any known metabolic or renal diseases? 
 
7.    Do you have any known health conditions?  
        High blood pressure?  
         Diabetes?  
        Thyroid issues? 
 
8.            If female, are you pregnant?  
 
9.                Do you consume >4 cups of coffee daily? 
      
 
Inclusion Criteria:  any question answered “yes” in this section will qualify 
the potential subject 
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  Yes     No 
 
1.          Do you train as a cyclist by riding your bicycle ≥ 3  
   hours per week? 
 
2. How many hours do you cycle per week? ________________ 
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Appendix E: Exercise Log 
Date: __________________________________ 
Mileage: ________________________________ 
Exercise Time: ___________________________   
Intensity of Exercise  
(6=rest → 20=maximal): ____________________  
Comments:  
 
 
 
Date: __________________________________     
Mileage: _______________________________ 
Exercise Time: __________________________   
Intensity of Exercise  
(6=rest → 20=maximal): ____________________   
Comments:  
 
 
 
Date: _________________________________     
Mileage: _______________________________ 
Exercise Time: __________________________   
Intensity of Exercise  
(6=rest → 20=maximal): ____________________   
Comments: 
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Appendix F: Nutrition Log 
Time 
Food/Beverage 
Consumed 
Food Item and Method of 
Preparation 
Amount Eaten 
(in cups, tablespoons, 
ounces, etc.) 
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Appendix G: Caffeine Recall 
7-Day Caffeine Recall 
 
ID#_________________  Study ___________  Trial ____________Date______________ 
 
Date Amount consumed Type of Caffeine 
Consumed 
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Appendix H: Rating of Breathlessness Questionnaire 
Subject: _____       Date: __________     Test:  _____________ RPB: ___   
 
 
STANDARD RESPIRATORY DEBRIEFING (Original A): 
 
Look over the following symptom list and select (circle) the top 3 descriptors 
that best describe the respiratory sensations you felt during the exercise. 
 
1. My breath does not go in all the way. 
2. My breathing requires effort. 
3. I feel that I am smothering. 
4. I feel hunger for air. 
5. My breathing is heavy. 
6. I feel out of breath. 
7. My chest feels tight. 
8. My breathing requires work. 
9. I feel that I am suffocating. 
10. My chest is constricted. 
11. I feel that my breathing is rapid. 
12. My breathing is shallow. 
13. I feel that I am breathing more. 
14. I cannot get enough air. 
15. My breath does not go out all the way. 
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Appendix I: Visual Analog Scale Questionnaire 
Subject: _____       Date: __________     Test:  _____________      RPB: ___                               
 
1)  Indicate along the scale below how unpleasant or disturbing your 
breathlessness was when your rating was highest. 
 
   
      
                              
                  Not bad at all                                                                     Maximal 
                                                                                                           imaginable 
 
 
 
 
2)  What kind of negative feelings accompany your breathlessness? Check along 
each scale below the intensity of each feeling as it related to your 
breathlessness when your rating was highest. 
 
 
                                                                                                            Maximal  
                      None                                                                           imaginable 
 
Depression 
 
 
Anxiety 
 
 
Frustration 
 
 
Anger 
 
 
Fear  
 
                     None                                                                             Maximal 
                                                                                                         imaginable 
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Appendix J: Rating of Perceive Breathlessness Scale  
Rate of Perceived Breathlessness (RPB) 
0 Nothing at all  
0.5 Very, very weak (just noticeable) 
1 Very weak 
2 Weak (light) 
3 Moderate 
4 Somewhat strong 
5 Strong (heavy) 
6 
 
7 Very strong 
8 
 
9 
 
10 Very, very strong (almost max) maximal  
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Appendix K: Rating of Perceived Breathlessness Description  
 
This is a scale for rating: 
BREATHLESSNESS 
 
 
 
 
 The number 0 represents no breathlessness. The number 10 represents the 
strongest or greatest breathlessness that you have ever experienced. Each minute during 
the exercise test you will be asked to point to a number, with your finger, which 
represents your perceived level of breathlessness at the time. The number will be repeated 
out loud in order to confirm your choice. During the exercise test you may have an even 
stronger or greater intensity of breathlessness than you have previously experienced. You 
should then point to the word “maximal” if the severity is greater than 10. You can tell us 
this number after the mouthpiece has been removed. 
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Appendix L: Rating of Perceived Unpleasantness Scale  
Rate of Unpleasantness  (RPU) 
0 Not unpleasant 
0.5 Very, very weak (just noticeable) 
1 Very weak unpleasantness 
2 Weak (light) unpleasantness 
3 Moderate unpleasantness 
4 Somewhat strong unpleasantness 
5 Strong (heavy) unpleasantness 
6 
 
7 Very unpleasant 
8 
 
9 
 
10 Maximal imaginable unpleasantness 
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Appendix M: Rating of Unpleasantness Description  
 
This is a scale for rating: 
 
UNPLEASANTNESS 
OF 
BREATHLESSNESS 
 
 
Unpleasantness expresses the affective evaluation of the sensation regardless of 
whether the intensity is high or low. Unpleasantness describes how much you affectively 
dislike something or feel terrified by it. A low unpleasantness indicates that the perceived 
breathlessness does not feel bad. A high unpleasantness signifies that the breathlessness 
feels very bad or terrifying regardless of whether the intensity of the sensation is high or 
low. 
During the exercise test you will be asked to point to a number, with your finger, 
which represents your perceived level of the unpleasantness of breathlessness at the time. 
The number will be repeated out loud in order to confirm your choice.  
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Appendix N: Rating of Perceived Exertion Scale  
 
Rate of Perceived Exertion  
6 No exertion at all  
7 
 
8 Extremely Light 
9 
 
10 
 
11 Light 
12 
 
13 Somewhat Hard 
14 
 
15 Hard (heavy)  
16 
 
17 Very Hard  
18  
19 Extremely Hard  
20  Maximal exertion 
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Appendix O: Rating of Perceived Exertion Description  
 
This is a scale for rating: 
PERCIEVED EXERTION 
 
 During the graded exercise test we want you to pay close attention to how hard 
the work rate is for you. The feeling should be your total amount of exertion and fatigue, 
combining all sensations and feelings of physical stress, effort and fatigue. Don’t concern 
yourself with any one factor such as leg pain, shortness of breath or exercise intensity, 
but try to concentrate on your total, inner feeling of exertion. Don’t underestimate or 
overestimate, just be as accurate as possible. 
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Appendix P: Leg Muscle Pain Scale 
 
Leg Muscle Pain Rating   
0 No pain at all  
0.5 Very faint pain (just noticeable)  
1 Weak Pain  
2 Mild Pain  
3 Moderate Pain  
4 Somewhat strong pain  
5 Strong pain 
6 
 
7 Very strong  
8 
 
9 
 
10 Extremely intense pain (almost unbearable)  
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Appendix Q: Leg Muscle Pain Description 
 
 
Leg Muscle Pain Instructions 
 
You are about to undergo an exercise test. The scale before you contains the numbers 0-
10. You will use this scale to assess perceptions of pain in your legs during and after the 
exercise test. In this context, pain is defined as the intensity of hurt that you feel. Don't 
underestimate or overestimate the degree of hurt you feel, just try to estimate it as 
honestly and objectively as possible. 
The numbers on the scale represent a range of pain intensity from“very faint pain” 
(number 1/2) to “extremely intense pain-almost unbearable” (number 10). When you feel 
no pain in your legs, you should respond with the number 0.  
Repeatedly during the test you will be asked to rate the feelings of pain in your legs. 
When rating these pain sensations, be sure to attend only to the specific sensations in 
your legs and not report other pains you may be feeling(e.g., seat discomfort). 
It is very important that your ratings of pain intensity reflect only the degree of hurt you 
are feeling in your legs either during exercise or following exercise as pain perceptions 
are abating. Do not use your ratings as an expression of fatigue (i.e., inability of the 
muscle to produce force) or relief that the exercise task is completed. 
In summary you will be asked to: (i) provide pain intensity ratings in your legs only; (ii) 
give ratings as accurately as possible; and (iii) not under- or overestimate the pain, but 
simply rate your pain honestly. You should use the verbal expressions to help rate your 
perceptions.  
 
 
 
Cook et al., 1997 
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